Oncotarget

Methodological Reports:

A Gene Expression Profile Test for the Differential Diagnosis of Ovarian Versus Endometrial Cancers

Anita Lal _, Rebecca Panos, Mira Marjanovic, Michael Walker, Eloisa Fuentes, Daniel S. Kapp, W David Henner, Ljubomir J. Buturovic and Meredith Halks-Miller

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2012; 3:212-223. https://doi.org/10.18632/oncotarget.450

Metrics: PDF 1505 views  |   HTML 1962 views  |   ?  


Abstract

Anita Lal1, Rebecca Panos1, Mira Marjanovic1, Michael Walker1, Eloisa Fuentes1, Daniel S Kapp2, W. David Henner1, Ljubomir J. Buturovic1 and Meredith Halks-Miller1

1 Pathwork Diagnostics, Redwood City, CA-94063

2 Department of Radiation Oncology, Stanford University, Stanford, CA-94305

Received: January 15, 2012; Accepted: February 21, 2012; Published: February 23, 2012;

Keywords: gene expression, tissue of origin, endometrial cancer, ovarian cancer, diagnostic test

Correspondence:

Anita Lal,

Abstract

We have developed a gene expression profile test (Pathwork Tissue of Origin Endometrial Test) that distinguishes primary epithelial ovarian and endometrial cancers in formalin-fixed, paraffin-embedded (FFPE) specimens using a 316–gene classification model. The test was validated in a blinded study using a pre-specified algorithm and microarray files for 75 metastatic, poorly differentiated or undifferentiated specimens with a known ovarian or endometrial cancer diagnosis. Measures of test performance include a 94.7% overall agreement with the known diagnosis, an area under the ROC curve (AUC) of 0.997 and a diagnostic odds ratio (DOR) of 406. Ovarian cancers (n=30) gave an agreement of 96.7% with the known diagnosis while endometrial cancers (n=45) gave an agreement of 93.3%. In a precision study, concordance in test results was 100%. Reproducibility in test results between three laboratories was 94.3%. The Tissue of Origin Endometrial Test can aid in resolving important differential diagnostic questions in gynecologic oncology.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 450